CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Nick Leschly, chief bluebird, will present at the 34th annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 4:00 p.m. PST. The conference is being held January 11-14, 2016 at the Westin St. Francis in San Francisco.
To access the live webcast of bluebird bio’s presentation and subsequent breakout session, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the conference.
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate currently in a Phase 2/3 study, called the Starbeam Study, for
the treatment of childhood cerebral adrenoleukodystrophy, and its
LentiGlobin® BB305 product candidate, currently in three
clinical studies for the treatment of beta-thalassemia major and severe
sickle cell disease. bluebird bio’s oncology pipeline is built upon the
company’s leadership in lentiviral gene delivery and T cell engineering,
with a focus on developing novel T cell-based immunotherapies, including
chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies.
bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T
program partnered with Celgene and focused on hematologic malignancies.
bluebird bio also has discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, and Paris, France.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
bluebird bio’s existing product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk that
previously conducted studies involving similar product candidates will
not be repeated or observed in ongoing or future studies involving
current product candidates, the risk of cessation or delay of any of the
ongoing or planned clinical studies and/or our development of our
product candidates, the risk of a delay in the enrollment of patients in
our clinical studies, the risk that our collaboration with Celgene will
not continue or will not be successful, and the risk that any one or
more of our product candidates will not be successfully developed and
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent quarterly report on
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the Securities
and Exchange Commission. All information in this press release is as of
the date of the release, and bluebird bio undertakes no duty to update
this information unless required by law.